用eGFR改善心血管疾病风险评估

Future Prescriber Pub Date : 2008-08-08 DOI:10.1002/fps.22

Sue Lyon

{"title":"用eGFR改善心血管疾病风险评估","authors":"Sue Lyon","doi":"10.1002/fps.22","DOIUrl":null,"url":null,"abstract":"<p>A quiet revolution is taking place within the NHS as laboratories grad-ually switch from serum creatinine to estimated glomerular filtration rate (eGFR) as the prime measure of renal function. This change follows recommendations in the National Service Framework for Renal Services,1 but the move will have an impact far beyond the renal com-munity, affecting health profess-ionals and patients throughout primary and secondary care. Copyright © 2006 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 1","pages":"26-28"},"PeriodicalIF":0.0000,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.22","citationCount":"0","resultStr":"{\"title\":\"Improving CVD risk assessment with eGFR\",\"authors\":\"Sue Lyon\",\"doi\":\"10.1002/fps.22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A quiet revolution is taking place within the NHS as laboratories grad-ually switch from serum creatinine to estimated glomerular filtration rate (eGFR) as the prime measure of renal function. This change follows recommendations in the National Service Framework for Renal Services,1 but the move will have an impact far beyond the renal com-munity, affecting health profess-ionals and patients throughout primary and secondary care. Copyright © 2006 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"7 1\",\"pages\":\"26-28\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.22\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Improving CVD risk assessment with eGFR

A quiet revolution is taking place within the NHS as laboratories grad-ually switch from serum creatinine to estimated glomerular filtration rate (eGFR) as the prime measure of renal function. This change follows recommendations in the National Service Framework for Renal Services,1 but the move will have an impact far beyond the renal com-munity, affecting health profess-ionals and patients throughout primary and secondary care. Copyright © 2006 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量